Beyond the pandemic: New vaccine pricing model
Third in the rankings of most read stories last month was an article about Pfizer raising the price of its COVID-19 shots in the US in Q1 2023.
This price model reflects the transition from the pandemic model to normal procurement paradigms, higher distribution costs as well as a transition from multidose vials to the single-dose version of the vaccine, said the drug maker.
Photo credit: GettyImages/sorbetto
